Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Sonnet Biotherapeutics stock
Learn how to easily invest in Sonnet Biotherapeutics stock.
Sonnet Biotherapeutics is a biotechnology business based in the US. Sonnet Biotherapeutics shares (SONN) are listed on the NASDAQ and all prices are listed in US Dollars. Sonnet Biotherapeutics employs 12 staff and has a trailing 12-month revenue of around $349,943.
How to buy Sonnet Biotherapeutics stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – SONN. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
- Get free stock upon signup
- Earn 4% interest on uninvested cash with Robinhood Gold
- Get 1% match on contributions to a Robinhood IRA
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.
Sonnet Biotherapeutics stock price (NASDAQ: SONN)Use our graph to track the performance of SONN stocks over time.
Sonnet Biotherapeutics shares at a glance
|Latest market close||$1.16|
|52-week range||$0.91 - $9.37|
|50-day moving average||$1.13|
|200-day moving average||$2.68|
|Wall St. target price||$18.90|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-0.60|
Buy Sonnet Biotherapeutics stocks from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Sonnet Biotherapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Sonnet Biotherapeutics price performance over time
|1 week (2023-01-24)||-0.85%|
|1 month (2022-12-30)||0.87%|
|3 months (2022-10-31)||-39.90%|
|6 months (2022-07-29)||329.63%|
|1 year (2022-01-31)||254.74%|
|2 years (2021-01-29)||-55.89%|
|3 years (2020-01-31)||81.19%|
|5 years (2018-01-30)||3.8699|
Sonnet Biotherapeutics financials
|Gross profit TTM||$-21,094,076|
|Return on assets TTM||-106.5%|
|Return on equity TTM||-301.42%|
|Market capitalisation||$9.1 million|
TTM: trailing 12 months
Sonnet Biotherapeutics share dividends
We're not expecting Sonnet Biotherapeutics to pay a dividend over the next 12 months.
Have Sonnet Biotherapeutics's shares ever split?
Sonnet Biotherapeutics's shares were split on a 1:14 basis on 18 September 2022. So if you had owned 14 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sonnet Biotherapeutics shares – just the quantity. However, indirectly, the new 1300% higher share price could have impacted the market appetite for Sonnet Biotherapeutics shares which in turn could have impacted Sonnet Biotherapeutics's share price.
Sonnet Biotherapeutics share price volatility
Over the last 12 months, Sonnet Biotherapeutics's shares have ranged in value from as little as $0.91 up to $9.3716. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sonnet Biotherapeutics's is 0.5851. This would suggest that Sonnet Biotherapeutics's shares are less volatile than average (for this exchange).
Sonnet Biotherapeutics overview
Sonnet BioTherapeutics Holdings, Inc. , a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer and is under phase 1 trial. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy and is under Phase Ib/IIa study; and SON-1210, a bispecific compound developed for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6.
Frequently asked questionsWhat percentage of Sonnet Biotherapeutics is owned by insiders or institutions?
Currently 2.127% of Sonnet Biotherapeutics shares are held by insiders and 3.249% by institutions. How many people work for Sonnet Biotherapeutics?
Latest data suggests 12 work at Sonnet Biotherapeutics. When does the fiscal year end for Sonnet Biotherapeutics?
Sonnet Biotherapeutics's fiscal year ends in December. Where is Sonnet Biotherapeutics based?
Sonnet Biotherapeutics's address is: 100 Overlook Center, Princeton, NJ, United States, 08540 What is Sonnet Biotherapeutics's ISIN number?
Sonnet Biotherapeutics's international securities identification number is: US83548R1059 What is Sonnet Biotherapeutics's CUSIP number?
Sonnet Biotherapeutics's Committee on Uniform Securities Identification Procedures number is: 15930P503
More guides on Finder
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
How to research stocks
Learn about stock analysis and how to use it to find the right company to buy.
Ask an Expert